Clinical Report: Biomarkers for Diagnosing Ischemic Stroke
Overview
This review evaluates the potential of various biomarkers in blood, urine, and saliva for the diagnosis of ischemic stroke (IS). While blood-based markers show promise, no single biomarker has proven sufficient for early diagnosis, highlighting the need for multi-marker strategies.
Background
Ischemic stroke is a leading cause of mortality and long-term disability, necessitating rapid diagnosis and intervention to minimize brain damage. Current diagnostic methods rely heavily on neuroimaging, which may not be available in all settings. This underscores the importance of identifying reliable biomarkers that can facilitate timely diagnosis and differentiation from other stroke types.
Data Highlights
No single biomarker or biofluid has been validated for early ischemic stroke diagnosis; blood-based markers are the most advanced, but many have limitations in specificity and kinetics.
Key Findings
Blood-based biomarkers, particularly glial fibrillary acidic protein, show high specificity for early stroke subtyping.
Urine and saliva biomarkers are still experimental and lack validation in larger acute patient populations.
No single biomarker is currently sufficient for early ischemic stroke diagnosis.
Multi-marker strategies and standardized methods are essential for future advancements.
Timely reperfusion is critical to saving viable brain tissue in ischemic stroke.
Clinical Implications
Healthcare professionals should remain aware that while biomarkers may aid in the diagnosis of ischemic stroke, they are not yet a replacement for neuroimaging. Continued research into multi-marker approaches may enhance diagnostic accuracy in the future.
Conclusion
The search for effective biomarkers in diagnosing ischemic stroke is ongoing, with current evidence suggesting that a combination of markers may be necessary for reliable early diagnosis.
